Untargeted Lipidomics in Fabry Disease of Urine Samples by Low-Resolution Flow Injection Mass Spectrometry (ESI(±)-LTQ MS).

Background: Fabry disease (FD) is a lysosomal storage disease caused by genetic mutations related to the coding of the enzyme α-galactosidase A, which is responsible for the metabolism of glycosphingolipids such as globotriaosylceramide and globotriaosylsphingosine. The accumulation of these and other metabolites can occur in various types of cells and impair the functioning of multiple organs and systems, such as the heart, brain, and kidneys. However, with early diagnosis and appropriate therapeutic intervention, the clinical outcome can be significantly improved. This study aimed to analyze the performance of new diagnostic methods for FD using the broad field of lipidomics combined with multivariate analyses, proposing the use of urine as a specimen.

Materials And Methods: urine samples were collected from patients with both confirmed (Case) and negative (Control) diagnoses of FD, which were later processed for specific lipid extraction. After extraction, 81 samples (44 cases and 37 controls) were subjected to mass spectrometry analysis, with direct infusion and electrospray ionization in both positive and negative modes (ESI(±)). After spectral acquisition, the data were processed and analyzed using multivariate analysis methods such as Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA).

Results: the combination of both ionization modes for PLS-DA was able to differentiate between the Case and Control groups with 92% accuracy.

Conclusion: this paper suggests that the proposed method of application of lipidomics combined with multivariate analyses as a tool for early diagnosis of FD is promising, enabling and contributing to the improvement of healthcare for these patients.